COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Mohamed (RCT)86%0.14 [0.01-2.21]viral+0/53/5Improvement, RR [CI]TreatmentControlChoudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Guenezan (RCT)63%0.37 [0.06-1.63]viral load12 (n)12 (n)Elzein (DB RCT)89%0.11 [0.01-1.52]viral load25 (n)9 (n)Arefin (RCT)79%0.21 [0.08-0.54]viral+4/2719/27Tau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.09-0.36]6/37239/35682% improvementSeet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP45%0.55 [0.38-0.80]42/73564/61945% improvementAll studies72%0.28 [0.14-0.56]48/1,107103/97572% improvement6 povidone-iodine COVID-19 studiesc19pvpi.com 8/2/211 OT: comparison with other treatmentTau​2 = 0.28; I​2 = 42.2%; Z = 3.56 (p = 0.00018)Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Choudhury (RCT)88%0.12 [0.03-0.50]2/30317/303Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment88%0.12 [0.03-0.50]2/30317/30388% improvementAll studies88%0.12 [0.03-0.50]2/30317/30388% improvement1 povidone-iodine COVID-19 mortality resultc19pvpi.com 8/2/21Tau​2 = 0.00; I​2 = 0.0%; Z = 2.88 (p = 0.002)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Choudhury (RCT)84%0.16 [0.09-0.28]hosp.12/30377/303Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment84%0.16 [0.09-0.28]12/30377/30384% improvementAll studies84%0.16 [0.09-0.28]12/30377/30384% improvement1 povidone-iodine COVID-19 hospitalization resultc19pvpi.com 8/2/21Tau​2 = 0.00; I​2 = 0.0%; Z = 6.21 (p < 0.0001)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Seet (CLUS. RCT)31%0.69 [0.37-1.01]338/735433/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP31%0.69 [0.37-1.01]338/735433/61931% improvementAll studies31%0.69 [0.63-0.76]338/735433/61931% improvement1 povidone-iodine COVID-19 case resultc19pvpi.com 8/2/211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 7.77 (p < 0.0001)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Choudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment88%0.12 [0.03-0.50]2/30317/30388% improvementSeet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP45%0.55 [0.38-0.80]42/73564/61945% improvementAll studies70%0.30 [0.07-1.32]44/1,03881/92270% improvement2 povidone-iodine COVID-19 serious outcomesc19pvpi.com 8/2/211 OT: comparison with other treatmentTau​2 = 0.90; I​2 = 75.4%; Z = 1.59 (p = 0.056)Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Mohamed (RCT)86%0.14 [0.01-2.21]viral+0/53/5Improvement, RR [CI]TreatmentControlChoudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Choudhury (RCT)84%0.16 [0.09-0.28]hosp.12/30377/303Choudhury (RCT)96%0.04 [0.02-0.07]viral+8/303213/303Guenezan (RCT)63%0.37 [0.06-1.63]viral load12 (n)12 (n)Elzein (DB RCT)89%0.11 [0.01-1.52]viral load25 (n)9 (n)Arefin (RCT)79%0.21 [0.08-0.54]viral+4/2719/27Arefin (RCT)89%0.11 [0.03-0.41]viral+2/2719/27Arefin (RCT)53%0.47 [0.26-0.85]viral+9/2719/27Arefin (RCT)80%0.20 [0.09-0.44]viral+5/2725/27Arefin (RCT)64%0.36 [0.21-0.62]viral+9/2725/27Arefin (RCT)74%0.26 [0.19-0.37]viral+29/13544/54Seet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Seet (CLUS. RCT)31%0.69 [0.37-1.01]cases338/735433/619OT​1povidone-iodine COVID-19 outcomesc19pvpi.com 8/2/21Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Molnupiravir
Nitazoxanide
Povidone-Iodine
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Feedback